← back to search

Ping Yue

First Hospital of Lanzhou University · CN
Area of research
Molecular Biology · Global and Planetary Change
Research interest
Research interests include Cell death mechanisms and regulation, PI3K/AKT/mTOR signaling in cancer, Climate variability and models, and Plant Water Relations and Carbon Dynamics.
h-index
53
citations
8,959
works
459
NIH funding
primary concept
email

Recent publications

Safety of Early Oral Refeeding in Patients With Chronic Pancreatitis After Extracorporeal Shock Wave Lithotripsy of Pancreatic Stone (SHEEL): A Multicenter Randomized Controlled Trial
American Journal of Gastroenterology 2025cited by 1position: contributordoi
Is endoscopic radiofrequency ablation safe and effective for treating rare neuroendocrine tumors of the minor papilla?
2025cited by 0position: contributordoi
Innovative application of a cystotome in the recanalization of a tight pancreatic duct stricture for abscess drainage.
2024cited by 0position: contributordoi
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Frontiers in Pharmacology 2023cited by 40position: middledoi
The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review
Frontiers in Microbiology 2023cited by 26position: middledoi
Safety of high-carbohydrate fluid diet 2 h versus overnight fasting before non-emergency endoscopic retrograde cholangiopancreatography: A single-blind, multicenter, randomized controlled trial
Chinese Medical Journal 2023cited by 3position: middledoi
Taking a high-carbohydrate liquid diet two hours before ERCP in non-emergency patients was as safe as overnight fasting: A single-blind, multicentre, randomised controlled trial
Clinical Nutrition ESPEN 2023cited by 0position: middledoi
A novel machine learning model and a public online prediction platform for prediction of post-ERCP-cholecystitis (PEC)
EClinicalMedicine 2022cited by 26position: middledoi
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey
HPB 2021cited by 6position: middledoi
Optimal dilation time for combined small endoscopic sphincterotomy and balloon dilation for common bile duct stones: a multicentre, single-blinded, randomised controlled trial
˜The œLancet. Gastroenterology & hepatology 2019cited by 43position: middledoi
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Cancer Letters 2016cited by 182position: middledoi
Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition
Journal of Biological Chemistry 2016cited by 31position: middledoi
mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation
Molecular and Cellular Biology 2015cited by 52position: middledoi
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells
Cancer Letters 2015cited by 52position: middledoi
Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling
Oncotarget 2015cited by 49position: middledoi
The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
Oncotarget 2015cited by 43position: middledoi
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
Oncotarget 2015cited by 38position: middledoi
Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Cancer Medicine 2014cited by 89position: middledoi
Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth
Cancer Research 2014cited by 50position: middledoi
The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis
Molecular Cancer 2013cited by 73position: middledoi
Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation
Journal of Biological Chemistry 2013cited by 59position: middledoi
mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis
Cancer Research 2013cited by 37position: middledoi
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer
Cancer Biology & Therapy 2012cited by 54position: middledoi
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo
Cancer Letters 2012cited by 53position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shi‐Yong Sun · Emory University14 papers (2012–2016)Fadlo R. Khuri · Emory University12 papers (2012–2015)Taofeek K. Owonikoko · New Mexico Cancer Center6 papers (2012–2016)Suresh S. Ramalingam · Emory University5 papers (2012–2016)Weilong Yao · Capital Medical University5 papers (2015–2016)Junghui Koo · Emory University4 papers (2012–2015)Wenbo Meng · First Hospital of Lanzhou University4 papers (2022–2023)Xingming Deng · Emory University4 papers (2013–2015)You-Take Oh · Emory University4 papers (2015–2016) · 3 papers (2024–2025)Jinqiu Yuan · Chinese People’s Liberation Army 263 hospital3 papers (2022–2023)Guojing Zhang · Chang'an University3 papers (2014–2016)Yanyan Lin · The First Affiliated Hospital, Sun Yat-sen University3 papers (2022–2023)Xun� Li · Fudan University3 papers (2022–2023)Yikun Li · Johns Hopkins University3 papers (2012–2016)Joseph W. Leung · University of California, Davis3 papers (2022–2023) · 2 papers (2024–2025)Hui Ren · Union Hospital2 papers (2012–2013)Jingshan Tong · UPMC Hillman Cancer Center2 papers (2015–2015)Jinyu Zhao · Jilin University2 papers (2023–2023)